Whole blood quantitative diagnostic, prognostic in vitro kit for monitoring the immune status prior to and following drug treatment

 

Whole blood quantitative diagnostic, prognostic in vitro kit for monitoring the immune status prior to and following drug treatment

Categories	Anti-inflammatory drugs, metabolic diseases, diabetes, Arteriosclerosis, chronic inflammation.
Patent Status	U.S. & EU patent pending, PCT publication no. WO 2005/025310 Additional provisional patent application has filled on July.4.2008.
Market Size	The annual sales potential is $ 1.4 billion in the U.S.A only.

Highlights

• A frequent monitoring of the immune system function of patients with diabetes and Arteriosclerosis could enable the prediction of complication appearance before they are evident and thus, enable an intelligent selection of the timing and drug/treatment to be used.
• Better diagnosis and prognosis of the immune status should improve the quality of life of such patients, and dramatically decrease the high expenses needed for treating the complications characterizing these common chronic diseases in their late stages.
• Clinical results in diabetic patients demonstrate the advantages of our novel kit compared with the golden standard CRP test.

Our Innovation

• Proprietary kit and method, enabling a better evaluation of the immune status and thus, improving treatment with immune system modulating drugs, by means of a simple blood test. 

Key Features

• Exclusive biomarker, which enables differentiation between an acute and chronic inflammation.
• Early diagnosis of immunosuppressed patients may reduce complications caused by chronic inflammation in Diabetes, Arteriosclerosis, IBD and other pathologies characterized by chronic inflammation (Huge potential market).
• Objective, quantitative and reliable tool to support decisions of treatments with anti-inflammatory drugs. (A unique solution to an unmet well-known need).
• Novel approach based on a profound understanding of the mechanism, which leads to a decreased activity of the immune system under chronic conditions, published in "Nature Immunology, "Journal of Immunology" and "Blood" journal.
• Excellent research supported by preliminary data in diabetes type 1 and type 2 patients and well-established results in animal models.

Development Milestones

• Preliminary clinical studies and kit optimization are in progress.
• GMP manufacturing.
• Research services combined the novel kit in post approval clinical trials of immune system modulator drugs are desired. 

 

Preclinical

 

U.S. & EU patent pending, PCT publication no. WO 2005/025310

Additional provisional patent application has filled on July.4.2008.